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The SGLT2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening 
heart failure in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure trial 
(DAPA-HF).  This report explores the effect of dapagliflozin on incident type 2 diabetes in the 
non-diabetic cohort enrolled in the trial. 
 
Research Design/Methods 
The subgroup of 2605 patients with heart failure and reduced ejection fraction (HFrEF), no prior 
history of diabetes, and a HbA1c of <6.5% at baseline was randomized to dapagliflozin 10 mg 
daily or placebo. In this exploratory analysis, surveillance for new onset diabetes was 
accomplished through periodic HbA1c testing as part of the study protocol and comparison 
between the treatment groups assessed through a Cox proportional hazards model. 
 
Results 
At baseline, the mean HbA1c was 5.8%. At 8 months, there were minimal changes, with a 
placebo-adjusted change in the dapagliflozin group of -0.04%. Over a median follow-up of 18 
months, diabetes developed in 93/1307 patients (7.1%) in the placebo group and 64/1298 (4.9%) 
in the dapagliflozin group. Dapagliflozin led to a 32% reduction in diabetes incidence (HR 0.68, 
95% CI, 0.50-0.94; p=0.019.)  More than 95% of the participants who developed type 2 diabetes 
had prediabetes at baseline (HbA1c 5.7-6.4%.) Participants who developed diabetes in DAPA-HF 
had a higher subsequent mortality than those who did not. 
Conclusions 
In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the 
incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration 
and in people without heart failure. 
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INTRODUCTION 
The prevalence of type 2 diabetes (T2D) continues to increase world-wide. Once established, T2D 
can lead to several complications that can reduce both the quality and duration of life, such as 
retinopathy, nephropathy, neuropathy, and a variety of cardiovascular problems including heart 
failure. While there have been major achievements over the past three decades in reducing the risk of 
these complications through optimal control of glycemia, blood pressure, and lipids, the best way to 
avoid them may be to prevent diabetes itself. T2D is preceded by a prolonged asymptomatic phase 
marked by mild hyperglycemia1, often referred to as ‘prediabetes.’ Safe and effective strategies to 
slow the otherwise progressive rise in blood glucose concentrations characterizing the transition 
from prediabetes to diabetes are needed. Several clinical trials have already demonstrated that T2D 
can in fact be prevented through lifestyle changes (healthy diet, weight loss, and increased physical 
activity), bariatric surgery, or the use of several glucose-lowering or weight loss medications.2 These 
studies have typically been conducted in higher risk patients, such as those with prediabetes (usually, 
impaired glucose tolerance [IGT]), obesity or both. 
 
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newer glucose-lowering oral agents 
originally approved for use in patients with T2D requiring additional glycemic control beyond 
metformin. They lower blood glucose and glycosylated hemoglobin (HbA1c) concentrations by 
inducing glucosuria. Notably, their use also leads to reductions in blood pressure and weight, but 
does not increase the risk of hypoglycemia as monotherapy or when paired with metformin. Recent 
outcome trials involving T2D patients at high cardiovascular or renal risk (or both) have also 
demonstrated significant benefits from SGLT2 inhibitors in reducing major adverse cardiovascular 
events, heart failure hospitalization, and the progression of chronic kidney disease.3 Such data have 
earned certain members of this class specific label indications to prevent cardiovascular and kidney 
complications. In the recently concluded Dapagliflozin and Prevention of Adverse-Outcomes in 
Heart Failure trial (DAPA-HF), some of these advantages were extended to patients with heart 
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failure and reduced ejection fraction (HFrEF) - the majority of whom did not have diabetes but were 
at high risk for its development.4 We took this opportunity to determine whether dapagliflozin 
could reduce the incidence of new T2D in patients enrolled in the trial without a prior diagnosis of 
diabetes and whose HbA1c was under the prevailing diagnostic threshold of 6.5%.1 
 
METHODS 
DAPA-HF was a multi-national randomized, placebo-controlled trial assessing the impact of 
dapagliflozin on cardiovascular mortality or worsening heart failure in 4744 patients with HFrEF. 
Inclusion criteria have been previously described.5 The major ones were a clinical diagnosis of heart 
failure with New York Heart Association (NYHA) functional class II-IV symptoms, left ventricular 
ejection fraction (LVEF) ≤40%, and elevated circulating concentrations of the N-terminal pro-B-
type natriuretic peptide (NT-proBNP). Key exclusion criteria were a prior history of type 1 diabetes 
and an estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2. 
 
After a screening visit during which inclusion and exclusion criteria were assessed and informed 
consent obtained, eligible patients were randomized to receiving once daily dapagliflozin 10 mg or 
matching placebo orally. Patients were evaluated at the clinical sites 2 weeks, 2 months and 4 
months after randomization, then every 4 months until the completion of the trial.  The primary 
outcome of DAPA-HF was the composite of cardiovascular death or worsening heart failure, 
including heart failure hospitalization or urgent treatment with intravenous therapy in the outpatient 
setting. Secondary outcomes were the occurrence of heart failure hospitalization or cardiovascular 
death; heart failure hospitalization (first and recurrent) and cardiovascular death; change in heart 
failure symptoms (based on the validated Kansas City Cardiomyopathy Questionnaire total 
symptom score [TSS])6 from baseline to 8 months; a composite worsening renal function outcome; 
and death from any cause. The incidence of a new diagnosis of T2D in patients without diabetes at 
baseline is the focus of this report. 
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All patients underwent HbA1c testing (in the non-fasted state, precluding simultaneous fasting 
plasma glucose measurements) at baseline and at each study visit  through a central laboratory, 
using the Bio-Rad Variant II HMT370 ion-exchange high-performance liquid chromatography 
(HPLC) assay (Bio-Rad, Hercules, CA, USA.) Those individuals with a prior diagnosis of T2D and 
those whose HbA1c was ≥6.5% at both the enrollment and randomization visits (i.e., repeated and 
confirmed, and therefore diagnosed with new T2D) were excluded from this analysis. The 
remaining participants constituted our study cohort, comprised of those with prediabetes at baseline 
(as per the definition of the American Diabetes Association [ADA] of a HbA1c between 5.7-6.4%)1 
and individuals considered to have normoglycemia (similarly defined a HbA1c <5.7%). Incident 
diabetes was defined as either a HbA1c of ≥6.5%, measured in the central laboratory, on two 
consecutive follow-up visits or a clinical diagnosis of diabetes outside of the trial leading to the 
initiation of a glucose lowering agent.  
 
STATISTICS 
 Baseline characteristics were compared between groups by using the two sample T-test and 
Wilcoxon rank-sum test for normal and non-normal continuous variables respectively, and the χ2 
test for categorical variables. In this exploratory analysis, the effect of dapagliflozin compared to 
placebo on incident diabetes was examined by means of hazard ratio (HR) and 95% confidence 
intervals (CI) derived from Cox proportional-hazards models with treatment allocation as the only 
factor in the model. To account for the competing risk of death from any cause, a further sensitivity 
analysis was performed using the method described by Fine and Gray, with incident diabetes as the 
outcome event and mortality due to any other cause as a competing risk.7 We also performed a third 
analysis using a logistic regression model adjusting for HbA1c at baseline to assess consistency of 
the data, irrespective of the initial glycemic status.  For all models, time-to-event was calculated as 
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time from randomization to new onset diabetes (with the time of the confirmatory HbA1c 
measurement used or the investigator reported date of diagnosis if recorded as an investigator-
reported event) or time to death or censor, whichever occurred first. A sensitivity analysis was 
performed using the date of the first HbA1c measurement ≥6.5% as the time-to-event of new-onset 
diabetes. The relative hazard of death from any cause and cardiovascular causes following a new 
diagnosis of DM was examined in a Cox proportional hazards model where an indicator of a new 
DM diagnosis was entered into the model as a time-updated covariate (with follow-up time starting 
at randomization). The period at risk prior to a new diagnosis of DM was attributed to the group 
with no diagnosis of DM in order to calculate incidence rates which reflect patients' time-updated 
event status. The model was repeated with adjustment for randomised treatment allocation, age, 
sex, region, race, NYHA functional classification, left ventricular ejection fraction, body mass 
index, pulse, systolic blood pressure, serum creatinine, log NT-proBNP, history of prior heart 
failure hospitalization, atrial fibrillation, stroke, myocardial infarction, hypertension, ischemic 
etiology and use of implantable cardioverter defibrillator and/or cardiac resynchronization therapy. 
This analysis was repeated for the endpoint of recurrent heart failure hospitalizations and 
cardiovascular death by means of a semiparametric proportional-rates model, in which the relative 
risk is reported as a rate ratio.8 Change in HbA1c over time was analyzed using a mixed model for 
repeated measurements (adjusted for baseline values, visit, randomized treatment and interaction of 
treatment and visit with a random intercept and slope per patient). All analyses were performed 




The median duration of follow-up was 18.2 months (interquartile range 14.2-21.5). As previously 
reported, in the placebo group, 502/2371 patients achieved the primary outcome of worsening heart 
failure or cardiovascular death (21.2%;15.6 events per 100 patient-years) whereas this occurred in 
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only 386/2373 patients in the dapagliflozin group (16.3%; 11.6 events per 100 patient-years.) The 
relative risk was thereby reduced by 26% (hazard ratio [HR][ 0.74, 95% confidence interval [CI] 
0.65, 0.85; p<0.001).4   This benefit appeared to extend to patients across baseline glycemic 
categories as there, with no heterogeneity in the primary outcome based on the presence (HR 0.75, 
95% CI, 0.63, 0.90, p=0.002) or absence (HR 0.73, 95% CI, 0.60, 0.88, p=0.002) of diabetes at 
baseline (p-value for interaction=0.80.)9 
 
Of the 4744 participants, 2139 (45%) were determined to have T2D at baseline, including 1983 
(42%) with a previous established diagnosis and an additional 156 (3.3%) being newly identified 
based on a confirmed HbA1c ≥6.5% at baseline. Of the 2605 (55%) without diabetes, 1748 (67%) 
had prediabetes and 857 (33%) had normoglycemia based on their HbA1c levels. The baseline 
characteristics of these groups are compared in Supplemental Table 1. Major differences between 
patients with prediabetes and those with an HbA1c in the normoglycemic range included age (67.1 
years ± 11.1 vs. 64.5 years ±12.5, p<0.001), BMI (27.4±5.8 vs. 26.8±5.6 kg/m2, p=0.023) and (as 
expected, based on our definitions) mean HbA1c (6.0%±0.3 vs. 5.3%±0.2, p<0.001).	Additionally, 
compared to normoglycemic patients, those with prediabetes more frequently had an ischemic 
etiology of heart failure, a lower mean eGFR and were more often treated with a diuretic. 
 
At baseline, amongst patients without diabetes, the mean HbA1c was 5.8% ±0.4% in the placebo 
group and 5.7% ±0.4% in the dapagliflozin group. At 8 months the mean HbA1c in the placebo 
group was 5.8% ±0.6%, 5.8% ±0.4% in the dapagliflozin group, with a placebo-corrected 
difference of -0.04% (95%CI -0.07 to -0.01). (Figure 1 A) These data varied slightly, based on the 
presence of prediabetes at baseline (Figure 1 B). In those with prediabetes, mean baseline HbA1c 
levels were 5.9%±0.3% and 6.0%±0.3% in those treated with dapagliflozin and placebo, 
respectively. At 8-months following randomization, mean HbA1c had fallen slightly in both 
groups: -0.08% (95% CI -0.10% to -0.06%) with dapagliflozin and by -0.04% (95% CI -0.07% to -
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0.02%) with placebo, yielding a placebo-corrected reduction of -0.04% (95% CI -0.07% to 0.00%, 
p=0.034) with dapagliflozin. In normoglycemic patients, mean baseline HbA1c in those treated 
with dapagliflozin and placebo was 5.3%±0.3% and 5.3%±0.2%, respectively. The corresponding 
changes in HbA1c at 8 months were +0.10% (95% CI +0.07 to +0.13) with dapagliflozin and 
+0.15% (95% CI +0.11 to +0.18) with placebo, yielding a placebo-corrected reduction of 0.05% (-
0.10% to 0.00%, p=0.051) with dapagliflozin. 
 
Amongst the 2605 trial participants without diabetes at baseline, 157 (6.0%) developed T2D during 
follow-up, 150 (95.5%) of whom had prediabetes based on the ADA definition and 136 [86.6%] of 
whom had prediabetes using the more restrictive 6.0-6.4% criterion of the International Expert 
Committee.10 Those with incident T2D had a higher mean baseline A1c (6.2 ±0.3 vs 5.7 ±0.4%; 
p<0.001), larger BMI (28.5 ±5.9 vs 27.1 ±5.7 kg/m2; p=0.003), lower eGFR (61.5 ±17.4 vs 68.2 
±19.3 ml/min/1.73 m2; p<0.001), and were more commonly using a statin (72% vs. 61%; p=0.006) 
than those whose HbA1c remained in the non-diabetic range (see Table 1.) 
 
Incident diabetes occurred in 93/1307 patients or 7.1% in the placebo group and 64/1298 or 4.9% in 
the dapagliflozin group. The rate per 100 patient-years was 5.0 (95% CI 4.1-6.1) versus 3.4 (2.7-
4.3) in the placebo and dapagliflozin groups, respectively. Using the Cox proportional hazards 
model, dapagliflozin led to a 32% reduction in diabetes incidence (HR 0.68 (95% CI, 0.50-0.94; 
p=0.019.) (See Figure 2) Separation of the event curves occurred early and was detectable by the 4-
month visit. Results were very similar using the Fine & Gray model, which accounted for the 
competing risk of mortality; the effect size here was virtually identical at 31% (HR 0.69 [0.50-
0.95]; p=0.021.) After adjustment for baseline HbA1c using a logistic regression model, the risk 
reduction was also similar (odds ratio, 0.72 [0.51-1.02]; p=0.068.)  Furthermore, the results of a 
sensitivity analysis using the date of the first HbA1c measurement ≥6.5% as the date of onset of 
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new diabetes gave a consistent hazard ratio of 0.68 (95% CI 0.50-0.94; p=0.019) in favor of 
dapagliflozin. 
	
Subgroup analysis  
There was no heterogeneity in the effect of dapagliflozin on diabetes prevention based on most key 
pre-specified subgroups, including sex, race, prediabetes status, NYHA class, and median baseline 
ejection fraction (at or below vs. above 32%). (See Supplemental Figure 1) The sole exceptions 
were age and baseline NT-proBNP levels. Younger individuals (≤65 years) and those with NT-
proBNP levels at or below the median appeared to garner a greater diabetes prevention benefit from 
active therapy than did older individuals ( ≥65 years) (interaction p value=0.04) and those with 
higher NTproBNP levels (interaction p value=0.01), respectively. These interactions, however, 
were not adjusted for multiple comparisons, and therefore could constitute chance findings.  
 
Effect of new-onset diabetes on risk of heart failure outcomes 
The relationship between new onset diabetes and heart failure outcomes is shown in Table 2. 
Amongst the primary and key secondary cardiovascular outcomes, we found two significant 
relationships with diabetes onset as a time-updated covariate. Following a new diagnosis of T2D, 
the rate of death from any cause was 16.6 per 100 patient-years compared to 7.2 for those who did 
not develop T2D during follow-up. The risk of death from any cause in patients with new onset 
T2D was more than two-fold that of patients who did not develop diabetes (unadjusted HR 2.20; 
95% CI 1.36-3.55). After adjustment for baseline variables and treatment assignment, this 
heightened risk remained significant (adjusted HR 1.70 [1.04-2.80]). Similar results were observed 
for death from cardiovascular causes. Considering the total number of heart failure hospitalizations 
(i.e., including recurrent events) and cardiovascular deaths, the event rates were 28.6 and 14.6 per 
100 patient-years in those with and without new onset DM, respectively, with an unadjusted HR of 
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In this exploratory analysis from the DAPA-HF trial, treatment with the SGLT2 inhibitor 
dapagliflozin reduced the risk of incident diabetes by 32%, an effect predominantly driven by 
individuals with prediabetes at baseline. The absolute risk reduction was 2.2% (95% CI 0.4-4.0%) 
with a number needed to treat (NNT) of 46 (95% CI 25-283) over 18 months for people with a 
diabetes incidence of 5.0 per 100 patient years. Of note the incidence rate in the placebo group was 
similar11 to or somewhat higher12-14 than those measured in other HFrEF trials in which incident 
diabetes was tracked. However, it was lower than that observed  in most traditional diabetes 
prevention trials which tended to be of longer duration, have generally enriched their cohorts for 
certain high-risk features (e.g., IGT, obesity) that ensured more frequent progression to diabetes, 
and used diagnostic techniques of greater sensitivity (e.g., oral glucose tolerance test.)15-19   
 
Previous metabolic studies in people with diabetes have demonstrated that SGLT2 inhibitors, in 
addition to reducing blood glucose and body weight, also improve insulin sensitivity20, decrease 
hyperinsulinemia20, and enhance pancreatic beta-cell function21. Each of these mechanisms, if they 
also occur in individuals in prediabetes, could serve to reduce their risk of developing T2D. In 
DAPA-HF, a large cardiovascular outcomes trial, we were not able to explore whether any of these 
mechanisms were responsible for dapagliflozin’s diabetes prevention effects. In this population, the 
potential additional benefit of increased physical activity in the dapagliflozin group, as suggested 
by improved scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ)6, may have 
contributed. Indeed, HF is known to be an insulin resistant state, likely the result of increased stress 
hormones and decreased physical activity.22 Anything that improves HF may improve the metabolic 
milieu in which diabetes tends to develop. Due to a relatively small numbers of cases of new onset 
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diabetes, we could not conduct an analysis to determine whether improved functional scores 
occurred more often in those whose HbA1c remained in non-diabetic range. 
 
With the increasing prevalence of diabetes throughout the world, simple, safe and effective 
preventive strategies are needed. Lifestyle changes are widely and appropriately endorsed as the 
optimal initial strategy, with relative risk reduction (RRR) for new onset diabetes reported to be as 
high as 58%.16,23   Several medications have also been tested, with benefits from certain glucose-
lowering agents, such as metformin (RRR 31%)16, rosiglitazone and pioglitazone (52% to 
72%)17,19,24, and acarbose (25%).15 Treatment with anti-obesity drugs has also been assessed, with 
RRR in the same general range (orlistat, 37%25; topiramate/phentermine, 71 to 79%26, and 
liraglutide, 79%27; and lorcaserin, 23%28.) Finally, several ACE inhibitors and angiotensin II 
receptor blockers (ARBs) have been shown to reduce the incidence of new diabetes (by 25% in a 
early pooled meta-analysis)29, including valsartan (RRR 14%) in a dedicated diabetes prevention 
trial.18 Of specific interest in a heart failure population, candesartan therapy was demonstrated to 
lower the risk of diabetes by 22%.30 It is therefore significant that dapagliflozin reduced the risk of 
new onset diabetes even in heart failure patients, the vast majority of whom were treated with an 
ACE inhibitor or ARBs. Of all of these potential therapies, only metformin has been recommended 
by the ADA for diabetes prevention23 and only in the highest risk patients with prediabetes. This is 
based on its long safety record, low cost, and the fact that it is already considered ‘foundation 
therapy’ for early T2D. Of note, no drug has yet been formally approved by the US Food and Drug 
Administration (FDA) for the specific indication of diabetes prevention. 
 
Diabetes prevention studies have predominately focused on the progression of hyperglycemia and 
have not been powered to assess the impact of diabetes prevention on chronic vascular 
complications. Logically, if diabetes is prevented, patients would be at lower risk for developing 
microvascular complications, such as diabetic retinopathy or diabetic nephropathy. In the Diabetes 
 13 
Prevention Program (DPP), the investigators did not find any overall differences in aggregate 
microvascular complications between the lifestyle, metformin and placebo groups.31 However, 
those trial participants who did not develop diabetes experienced less microvascular events than 
those who did.31 These data suggest that diabetes prevention could, over time, reduce at least some 
of the highly morbid complications of this disease.  
 
It is even more difficult to demonstrate any effect of diabetes prevention on macrovascular events, 
since atherosclerotic cardiovascular disease and its sequelae also develop in non-diabetic 
individuals and, moreover, are not as clearly related to the degree of hyperglycemia as are 
microvascular complications. In the DPP, those patients who were assigned to lifestyle intervention 
and who experienced reduced incidence of diabetes also enjoyed improvement in several 
cardiovascular risk factors -- but not in actual cardiovascular events.32 Indeed, any effect of diabetes 
prevention on actual cardiovascular complications may be difficult to confirm in a trial, given their 
multifactorial nature and the many years required for their evolution. In the Study to Prevent 
NIDDM (STOP-NIDDM) Trial, use of the alpha-glucosidase inhibitor acarbose reduced both the 
incidence of diabetes as well as that of myocardial infarction in IGT patients.33 However, the latter 
effect could not be confirmed in the larger Acarbose Cardiovascular Evaluation (ACE) trial.34 In 
Insulin Resistance Intervention after Stroke (IRIS) trial, treatment with the thiazolidinedione 
pioglitazone reduced the incidence of both stroke and myocardial infarction in an insulin resistant 
group of patients with recent stroke or transient ischemic attack (TIA)35 while also decreasing their 
development of new onset diabetes.24 It remains unknown, however, if these two effects were 
necessarily linked. Finally, indirect evidence from follow-up of the original Da Qing study cohort 
suggested that T2D prevention, at least through lifestyle changes, may eventually attenuate future 
all-cause mortality.36  
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DAPA-HF is noteworthy for diabetes specialists for three reasons. First, it is the first study to 
suggest a diabetes prevention effect from an SGLT2 inhibitor. Some might argue that diabetes 
prevention is not important in an older, sicker population of patients with limited life expectancy. 
However, this first foray into the field of diabetes prevention with SGLT2 inhibition could spark 
other trials in younger, healthier groups of patients  - who might benefit to a greater degree by 
avoiding or at least delaying incident diabetes..  Second, it is the first study to demonstrate that a 
single drug may prevent both diabetes and death, albeit in a specific group of patients with heart 
failure. Further investigation will, of course, be necessary to determine whether and to what extent 
these outcomes may be associated. Our finding that those patients who developed new onset 
diabetes had a higher mortality rate does not at all prove that diabetes prevention mediated this 
benefit. Indeed, in previous post-hoc analyses from other SGLT2i trials in patients with T2D, the 
cardiovascular benefits of this glucose-lowering class appear to be largely disassociated from its 
glucose-lowering effect.9,37 The patients who developed new-onset diabetes had more advanced 
heart failure at baseline and, therefore, were at higher risk initially. Also, since those participants 
who did not develop diabetes were more likely to be on dapagliflozin, our observations may be 
confounded by the effect of dapagliflozin on the cardiovascular outcomes, although we did adjust 
for randomized treatment assignment. Nonetheless, it is possible that preventing diabetes might 
play a role in improving heart failure outcomes since the coexistence of diabetes is known to 
worsen overall prognosis in heart failure patients. A recent large cohort study from Denmark, for 
example, revealed that the onset of diabetes after a first hospitalization for heart failure is associated 
with a nearly 50% higher mortality.38 Third, DAPA-HF is the first trial showing a reduction in 
incident diabetes without a significant effect on mean HbA1c. Each of the prior positive diabetes 
prevention trials that reported baseline and on-trial HbA1c levels have demonstrated small but 
significant differences in this biomarker of average glycemia between the active therapy and 
placebo groups.16,19,27,28 This has raised concerns that the diabetes “prevention” effects of the study 
drug may have merely reflected numerical reductions in glucose concentrations, and therefore 
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represented nothing more than a masking of the underlying disease process.39 Because there was no 
major change in mean HbA1c in the non-diabetic participants in DAPA-HF, such an argument may 
be less persuasive. Yet, since our outcome measure was essentially based on changes in HbA1c, 
differential effects of the two treatment arms on this measure at an individual patient level over 
time likely drove the risk reduction.  Admittedly, it is very difficult to disentangle the glucose 
lowering from the diabetes prevention effects of any diabetes medication.  Nonetheless, our 
findings may provide further insights into the underlying effect of SGLT2 inhibition on beta cell 
dysfunction in the progression from prediabetes to diabetes - a notion that will require further study 
of a more mechanistic nature. 
 
LIMITATIONS 
Our study has some several limitations. As noted, in diabetes prevention studies involving glucose 
lowering agents, questions arise as to whether the apparent reduction in the incidence of diabetes is 
measurable only because of transient reductions in glycemia, merely delaying diagnosis but not 
actually preventing disease progression per se. The lack of a significant effect of dapagliflozin on 
mean HbA1c may partially allay such concerns. Moreover, this may be a semantic argument since 
even a quantifiable delay in the diabetes diagnosis could still potentially mitigate the deleterious 
health effects of chronic hyperglycemia over time. We did not, however, conduct a wash-out at the 
end of the trial with retesting for diabetes to assess whether patients who remained non-diabetic 
during active therapy might experience an increased incidence after stopping study drug. 
Accordingly, we could not determine whether the effect of dapagliflozin on new onset diabetes 
would extend beyond the fixed duration of drug exposure. Traditional diabetes prevention trials 
have demonstrated a relatively rapid increase in diabetes incidence in a significant proportion of 
participants at the end of such a washout period.40 So prevention effects are likely to be strongest 
during active therapy with glucose-lowering agents and there is no a priori reason to think this 
would not be the case with an SGLT2i. In this event-driven heart failure study with a higher than 
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expected event rate for the primary outcome, the study duration was shorter than in most diabetes 
prevention trials. Whether the effect of dapagliflozin on new onset diabetes would persist beyond 
18 months is speculative. In the longer T2D prevention trials, the effects of the investigational agent 
appear to persist for up to 3-4 years with no narrowing of the event curves over time.16,17,25,27 
Because DAPA-HF was designed as a heart failure trial, we captured diabetes ‘events’ mainly on 
the basis of periodic measurement of HbA1c. We did not assess fasting plasma glucose or oral 
glucose tolerance, assessments which are more typical in standard diabetes prevention trials and, if 
performed, may potentially have affected the results.  We also did not measure erythropoietin levels 
(which have been reported to increase after SGLT2 inhibition.)  Conceivably increased red blood 
cell turnover, after erythropoietin stimulation might affect rates of hemoglobin glycation.  However, 
since the actual differences in HbA1c were minimal, we don’t feel this explains the differential 
effect on the incidence of new onset diabetes.  Finally, because of the population studied in DAPA-
HF, these data cannot necessarily be extrapolated to a non-HFrEF population, including those with 
heart failure with preserved ejection fraction (HFpEF) or those without heart failure.   
 
SUMMARY 
During active therapy, the SGLT2i dapagliflozin decreased the incidence of T2D by 32% in 2605 
participants in the DAPA-HF trial who did not have diabetes at baseline. This effect was principally 
driven by participants with prediabetes at baseline. Interestingly, this effect size is nearly identical 
to that demonstrated in the DPP with metformin16, the drug most commonly considered for use in 
diabetes prevention. While the major role of dapagliflozin in HFrEF is to reduce cardiovascular 
mortality and worsening of heart failure, decreasing the incidence of new diabetes may be 
considered an additional benefit. These data need to be confirmed with dapagliflozin and/or other 
SGLT2 inhibitors in trials of longer duration and in a broader population of patients with 
prediabetes who do not necessarily have heart failure. Finally, further investigation will also be 
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required to explore any potential links between diabetes prevention and the cardiovascular benefits 
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Figure 1. HbA1c levels over time in the dapagliflozin vs. placebo groups   
Panel A represents all patients without diabetes at baseline. In Panel B solid lines represent trial 
participants with prediabetes at baseline (HbA1c 5.7-6.4%) and dashed lines represent patients 
with normoglycemia at baseline (HbA1c <5.7%) In both groups, HbA1c changed minimally over 




Figure 2. Incidence of new onset T2D in dapagliflozin vs. placebo groups 
The hazard ratio for incident T2D in the dapagliflozin group compared with placebo was 0.68 
(95% CI, 0.50-0.94; p=0.019), with an early divergence of the event curves. 
 
Supplemental Figure 1. Effect of dapagliflozin on incident diabetes by relevant subgroups 
No heterogeneity of the treatment effect on incident T2D was found except for nominal 





Table 1: Baseline characteristics by new onset T2D status in patients without T2D at 
baseline 
 No New Onset T2D New Onset T2D p-value 
 N=2448 N=157  
Age – yr  66.2±11.7 66.7±10.7 0.55 
Sex -  no (%)   0.86 
Female 593 (24.2) 39 (24.8)  
Male 1,855 (75.8) 118 (75.2)  
Race – no. (%)†   0.41 
White 1,731 (70.7) 113 (72.0)  
Asian 593 (24.2) 32 (20.4)  
Black or African American 89 (3.6) 9 (5.7)  
Other 35 (1.4) 3 (1.9)  
Region – no.  (%)   0.31 
Asia/Pacific 586 (23.9) 31 (19.7)  
Europe 1,129 (46.1) 74 (47.1)  
North America 324 (13.2) 18 (11.5)  
South America 409 (16.7) 34 (21.7)  
Body-mass index§ 27.1±5.7 28.5±5.9 0.003 
HbA1c – % 5.7±0.4 6.2±0.3 <0.001 
Estimated GFR    
Mean – ml/min/1.73 m2 68.2±19.3 61.5±17.4 <0.001 
Rate < 60 ml/min/1.73 m2 – no. (%) 868 (35.5) 76 (48.4) 0.001 
Systolic Blood Pressure – mmHg 120.6±16.0 120.8±17.3 0.84 
NYHA functional classification – no.  (%)   0.40 
II 1,737 (71.0) 104 (66.2)  
III 692 (28.3) 51 (32.5)  
IV 19 (0.8) 2 (1.3)  
Left ventricular ejection fraction – % 30.9±6.9 30.5±6.8 0.42 
Median NT-proBNP (IQR) –  pg/ml 1406 (828-2463) 1585 (832-2984) 0.20 
Median KCCQ-TSS (IQR) 79.2 (61.5-92.7) 75.0 (60.4-88.5) 0.049 
Principal cause of heart failure – no. (%)   0.12 
Ischemic  1,249 (51.0) 92 (58.6)  
Non-ischemic 983 (40.2) 50 (31.8)  
Unknown 216 (8.8) 15 (9.6)  
Medical history – no. (%)    
Prior hospitalization for heart failure  1,128 (46.1) 74 (47.1) 0.80 
Atrial fibrillation 950 (38.8) 72 (45.9) 0.079 
Heart failure medication – no (%)    
Diuretic 1982 (81.0) 142 (90.4) 0.003 
ACE-inhibitor 1,402 (57.3) 87 (55.4) 0.65 
ARB 645 (26.3) 47 (29.9) 0.32 
Sacubitril-valsartan 266 (10.9) 13 (8.3) 0.31 
Beta-blocker 2,338 (95.5) 153 (97.5) 0.25 
Mineralocorticoid receptor antagonist 1,728 (70.6) 113 (72.0) 0.71 
Digitalis 421 (17.2) 37 (23.6) 0.042 
Statin 1,494 (61.0) 113 (72.0) 0.006 
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Data presented as mean (SD) unless otherwise indicated.  
Percentages may not total 100 because of rounding.  
ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, GFR 
glomerular filtration rate, IQR interquartile range, LVEF left ventricular ejection fraction, MRA 
mineralocorticoid receptor antagonist, N-terminal pro-B-type natriuretic peptide and NYHA New 
York Heart Association. KCCQ-TSS Kansas City Cardiomyopathy Questionnaire total symptom 
score - range from 0 to 100, with higher scores indicating fewer symptoms and physical 
limitations associated with heart failure. A score of 75 or above is considered to reflect 
satisfactory health status. 
† Race was reported by the investigators 









































Table 2: Primary and key secondary outcomes with the event of new-onset T2D as a time-
updated covariate. 
 
 Event rate/100 PY Unadjusted HR (95% 
CI) 
Adjusted HR (95% 
CI)* 
All-cause mortality  
No new-onset T2D (n=2448) 7.2 (6.4-8.1) 1.00 1.00 
New-onset T2D (n=157) 16.6 (10.5-26.3) 2.20 (1.36-3.55); p=0.001 1.70 (1.04-2.80); p=0.035 
Cardiovascular death 
No new-onset T2D (n=2448) 5.8 (5.1-6.7) 1.00 1.00 
New-onset T2D (n=157) 14.7 (9.0-24.1) 2.43 (1.46-4.06); p=0.001 1.77 (1.04-3.02); p=0.035 
Total HF hospitalizations (including recurrent) and cardiovascular death** 
No new-onset T2D (n=2448) 14.6 (13.4-15.9) 1.00 1.00 
New-onset T2D (n=157) 28.6 (20.1-40.6) 1.90 (1.18-3.05); p=0.008 1.37 (0.83-2.24); p=0.22 
 
*Adjusted for randomized treatment, age, sex, region, race, NYHA functional classification, left 
ventricular ejection fraction, body mass index, pulse, systolic blood pressure, serum creatinine, 
log NT-proBNP, history of previous HF hospitalization, atrial fibrillation, stroke, myocardial 
infarction, hypertension, ischemic etiology and use of implantable cardioverter defibrillator 
and/or cardiac resynchronization therapy.   
**Estimates presented are rate rat
